Newsroom | 55313 results
Sorted by: Latest
-
Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Announces Closing of Merger with Rallybio Corporation and Previously Announced $215 Million Concurrent Private Placement...
-
AN2 Therapeutics to Participate in 9th Annual Evercore Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Wednesday, December 2, 2026 at 8:20am ET and members of management will be available for 1x1 meetin...
-
Ataraxis AI to Present Nine Studies at SABCS 2026
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, announced today that it will present nine studies at the 2026 San Antonio Breast Cancer Symposium (SABCS), including several oral presentations. The research validates Ataraxis AI for prognosis and chemotherapy benefit prediction in the landmark Phase III TAILORx and SWOG-8814 trials and in multi-national real-world cohorts, with head-to-head comparisons against legacy genomic assays. Ataraxi...
-
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026 for the Company’s molgramostim inhalation solution (molgramostim) Biologics License Application (BLA) for the treatment of autoimmune PAP. The review of the BLA is ongoing...
-
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on November 16, 2026, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award...
-
United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal Disease
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of the UThymoKidney™ in patients with ESRD. The transplant operation was performed at NYU Langone Health. The ongoing EXTEND study will evaluate the safety and efficacy of the UThymoKidney in ESRD patients who are not eligible for conventional allogeneic kidney transplantation or wh...
-
Alterome Therapeutics Presents Preliminary Clinical Data from Ongoing Phase 1/1b Trial of ALTA3263 Demonstrating Antitumor Activity in KRAS-Mutant Colorectal and Pancreatic Cancers at the 38th EORTC-NCI-AACR Symposium
SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage precision oncology company focused on discovering and developing alteration-specific therapeutics to address oncogenic drivers, today announced the presentation of the preliminary clinical data from the Phase 1 dose-escalation portion of its ongoing Phase 1/1b clinical trial evaluating ALTA3263, an orally available KRAS-selective, pan-mutant, active/inactive (ON/OFF) inhibitor, in adult patients with KRAS-mutant advanced...
-
Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma
RAHWAY, N.J.--(BUSINESS WIRE)--TroFuse-015 Evaluating Sac-TMT Met Primary Endpoint of OS in 3rd-Line or Later Locally Adv. Unresectable or Metastatic Gastroesophageal Adenocarcinoma...
-
Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is scheduled to take place at 8:00 a.m. EST. The conference call and webcast details, including dial-in information and webcast link, will be posted on the Investor Relations section of Summit's website, www.smmttx.com. The archived webcast will be available through the company's website after the call has conclu...
-
Axoft Unveils Meaningful Clinical Momentum of Its Ultra-Soft Fleuron™ Brain Computer Interface Probes
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axoft, a neurotechnology company, today announced multiple data milestones from ongoing clinical use of its ultra-soft Fleuron™ Brain Computer Interface (BCI) depth probes at Mass General Brigham (MGB) and The Panama Clinic. Built to leverage the naturally scalable language of the brain, Axoft’s high-density BCIs use the company’s proprietary Fleuron material, which enables high quality neural data capture over longer periods of time due to the material’s supe...